Cargando…

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''

Detalles Bibliográficos
Autores principales:	Bowyer, Samantha, Prithviraj, Prashanth, Lorigan, Paul, Larkin, James, McArthur, Grant, Atkinson, Victoria, Millward, Michael, Khou, Muoi, Diem, Stefan, Ramanujam, Sangeetha, Kong, Ben, Liniker, Elizabeth, Guminski, Alexander, Parente, Phillip, Andrews, Miles C, Parakh, Sagun, Cebon, Jonathan, Long, Georgina V, Carlino, Matteo S, Klein, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396114/ https://www.ncbi.nlm.nih.gov/pubmed/28324885 http://dx.doi.org/10.1038/bjc.2017.59

Ejemplares similares

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
por: Venditti, Olga, et al.
Publicado: (2015)

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
por: Colston, Elizabeth, et al.
Publicado: (2018)

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
por: Da Gama Duarte, Jessica, et al.
Publicado: (2018)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

2081: Phenotypic characterization of the CD4+ T-cell response during anti-CTLA4 therapy with ipilimumab in melanoma patients
por: Sherani, Farha, et al.
Publicado: (2018)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
por: Voskens, Caroline J., et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
por: He, Mengnan, et al.
Publicado: (2017)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro
por: Rosskopf, Sandra, et al.
Publicado: (2019)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
por: Wagner, Michael J, et al.
Publicado: (2021)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
por: Leung, Anna M., et al.
Publicado: (2014)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
por: Klein, Oliver, et al.
Publicado: (2021)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells
por: Jayachandran, Aparna, et al.
Publicado: (2015)

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
por: Arce Vargas, Frederick, et al.
Publicado: (2018)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
por: Tarhini, Ahmad
Publicado: (2013)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
por: Salvatori, Erika, et al.
Publicado: (2022)

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
por: Seidel, Judith A., et al.
Publicado: (2018)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Micro-abnormalities in the retina and choroid induced by anti-CTLA4 treatment
por: Mukai, Ryo, et al.
Publicado: (2023)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5uupo2tclere8omqd0igpnu40e